Zymeworks Historical Balance Sheet

ZYME Stock

USD 12.62 0.27 2.19%

Trend analysis of Zymeworks Common Stock balance sheet accounts such as Total Assets of 486.2 B, Other Current Liab of 65.8 B, Total Current Liabilities of 92.7 B or Total Stockholder Equity of 355.7 B provides information on Zymeworks Common's total assets, liabilities, and equity, which is the actual value of Zymeworks Common Stock to its prevalent stockholders. By breaking down trends over time using Zymeworks Common balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Zymeworks Common Stock latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Zymeworks Common Stock is a good buy for the upcoming year.

Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Zymeworks Common Stock. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

About Zymeworks Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Zymeworks Common Stock at a specified time, usually calculated after every quarter, six months, or one year. Zymeworks Common Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Zymeworks Common and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Zymeworks currently owns. An asset can also be divided into two categories, current and non-current.

Zymeworks Common Balance Sheet Chart

At present, Zymeworks Common's Other Current Liabilities is projected to increase significantly based on the last few years of reporting. The current year's Total Current Liabilities is expected to grow to about 92.7 B, whereas Net Debt is projected to grow to (45.2 B).

Total Assets Other Current Liab Total Current Liabilities Other Liab

Add Fundamental

Total Assets

Total assets refers to the total amount of Zymeworks Common assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Zymeworks Common Stock books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Zymeworks Common balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Zymeworks Common Stock are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Most accounts from Zymeworks Common's balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Zymeworks Common Stock current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Current Watchlist to better understand how to build diversified portfolios, which includes a position in Zymeworks Common Stock. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

	2022	2023	2024	2025 (projected)
Other Current Liabilities	61.7M	39.8M	62.7B	65.8B
Total Assets	648.7M	580.9M	463.1B	486.2B

Other Current Liab Total Assets

Zymeworks Common balance sheet Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Short Long Term Debt	Total Current Assets	Short Term Debt	Intangible Assets	Common Stock	Property Plant Equipment
Total Assets		1.0	1.0	1.0	0.3	0.65	1.0	-1.0	-1.0	0.13	1.0	1.0	1.0	1.0	1.0	0.46	-0.95	1.0	1.0	1.0	-0.09	1.0	0.03	-0.26	1.0	0.7
Other Current Liab	1.0		1.0	1.0	0.3	0.65	1.0	-1.0	-1.0	0.13	1.0	1.0	1.0	1.0	1.0	0.46	-0.95	1.0	1.0	1.0	-0.09	1.0	0.03	-0.26	1.0	0.7
Total Current Liabilities	1.0	1.0		1.0	0.3	0.65	1.0	-1.0	-1.0	0.13	1.0	1.0	1.0	1.0	1.0	0.46	-0.95	1.0	1.0	1.0	-0.09	1.0	0.03	-0.26	1.0	0.7
Total Stockholder Equity	1.0	1.0	1.0		0.3	0.65	1.0	-1.0	-1.0	0.13	1.0	1.0	1.0	1.0	1.0	0.46	-0.95	1.0	1.0	1.0	-0.09	1.0	0.03	-0.26	1.0	0.7
Other Liab	0.3	0.3	0.3	0.3		0.8	0.3	-0.31	-0.31	0.83	0.3	0.3	0.3	0.3	0.3	0.87	-0.22	0.3	0.3	0.3	-0.17	0.3	0.42	0.68	0.3	0.7
Net Tangible Assets	0.65	0.65	0.65	0.65	0.8		0.65	-0.65	-0.65	0.78	0.66	0.65	0.65	0.65	0.65	0.92	-0.62	0.65	0.65	0.65	-0.26	0.65	0.55	0.39	0.65	0.95
Property Plant And Equipment Net	1.0	1.0	1.0	1.0	0.3	0.65		-1.0	-1.0	0.13	1.0	1.0	1.0	1.0	1.0	0.46	-0.95	1.0	1.0	1.0	-0.09	1.0	0.03	-0.26	1.0	0.7
Net Debt	-1.0	-1.0	-1.0	-1.0	-0.31	-0.65	-1.0		1.0	-0.13	-1.0	-1.0	-1.0	-1.0	-1.0	-0.48	0.93	-1.0	-1.0	-1.0	0.09	-1.0	-0.03	0.25	-1.0	-0.7
Retained Earnings	-1.0	-1.0	-1.0	-1.0	-0.31	-0.65	-1.0	1.0		-0.12	-1.0	-1.0	-1.0	-1.0	-1.0	-0.48	0.93	-1.0	-1.0	-1.0	0.09	-1.0	-0.03	0.26	-1.0	-0.7
Accounts Payable	0.13	0.13	0.13	0.13	0.83	0.78	0.13	-0.13	-0.12		0.13	0.13	0.13	0.13	0.13	0.83	-0.14	0.13	0.13	0.13	-0.07	0.13	0.55	0.73	0.13	0.71
Cash	1.0	1.0	1.0	1.0	0.3	0.66	1.0	-1.0	-1.0	0.13		1.0	1.0	1.0	1.0	0.46	-0.95	1.0	1.0	1.0	-0.09	1.0	0.03	-0.25	1.0	0.7
Non Current Assets Total	1.0	1.0	1.0	1.0	0.3	0.65	1.0	-1.0	-1.0	0.13	1.0		1.0	1.0	1.0	0.46	-0.95	1.0	1.0	1.0	-0.09	1.0	0.03	-0.26	1.0	0.7
Non Currrent Assets Other	1.0	1.0	1.0	1.0	0.3	0.65	1.0	-1.0	-1.0	0.13	1.0	1.0		1.0	1.0	0.46	-0.95	1.0	1.0	1.0	-0.09	1.0	0.03	-0.26	1.0	0.7
Cash And Short Term Investments	1.0	1.0	1.0	1.0	0.3	0.65	1.0	-1.0	-1.0	0.13	1.0	1.0	1.0		1.0	0.46	-0.95	1.0	1.0	1.0	-0.09	1.0	0.03	-0.26	1.0	0.7
Net Receivables	1.0	1.0	1.0	1.0	0.3	0.65	1.0	-1.0	-1.0	0.13	1.0	1.0	1.0	1.0		0.46	-0.95	1.0	1.0	1.0	-0.09	1.0	0.03	-0.26	1.0	0.7
Common Stock Shares Outstanding	0.46	0.46	0.46	0.46	0.87	0.92	0.46	-0.48	-0.48	0.83	0.46	0.46	0.46	0.46	0.46		-0.35	0.46	0.46	0.46	-0.21	0.46	0.61	0.49	0.46	0.89
Inventory	-0.95	-0.95	-0.95	-0.95	-0.22	-0.62	-0.95	0.93	0.93	-0.14	-0.95	-0.95	-0.95	-0.95	-0.95	-0.35		-0.95	-0.95	-0.95	0.09	-0.95	-0.04	0.24	-0.95	-0.67
Other Current Assets	1.0	1.0	1.0	1.0	0.3	0.65	1.0	-1.0	-1.0	0.13	1.0	1.0	1.0	1.0	1.0	0.46	-0.95		1.0	1.0	-0.09	1.0	0.03	-0.26	1.0	0.7
Other Stockholder Equity	1.0	1.0	1.0	1.0	0.3	0.65	1.0	-1.0	-1.0	0.13	1.0	1.0	1.0	1.0	1.0	0.46	-0.95	1.0		1.0	-0.09	1.0	0.03	-0.26	1.0	0.7
Total Liab	1.0	1.0	1.0	1.0	0.3	0.65	1.0	-1.0	-1.0	0.13	1.0	1.0	1.0	1.0	1.0	0.46	-0.95	1.0	1.0		-0.09	1.0	0.03	-0.26	1.0	0.7
Short Long Term Debt	-0.09	-0.09	-0.09	-0.09	-0.17	-0.26	-0.09	0.09	0.09	-0.07	-0.09	-0.09	-0.09	-0.09	-0.09	-0.21	0.09	-0.09	-0.09	-0.09		-0.09	-0.11	0.22	-0.09	-0.12
Total Current Assets	1.0	1.0	1.0	1.0	0.3	0.65	1.0	-1.0	-1.0	0.13	1.0	1.0	1.0	1.0	1.0	0.46	-0.95	1.0	1.0	1.0	-0.09		0.03	-0.26	1.0	0.7
Short Term Debt	0.03	0.03	0.03	0.03	0.42	0.55	0.03	-0.03	-0.03	0.55	0.03	0.03	0.03	0.03	0.03	0.61	-0.04	0.03	0.03	0.03	-0.11	0.03		0.41	0.03	0.58
Intangible Assets	-0.26	-0.26	-0.26	-0.26	0.68	0.39	-0.26	0.25	0.26	0.73	-0.25	-0.26	-0.26	-0.26	-0.26	0.49	0.24	-0.26	-0.26	-0.26	0.22	-0.26	0.41		-0.26	0.33
Common Stock	1.0	1.0	1.0	1.0	0.3	0.65	1.0	-1.0	-1.0	0.13	1.0	1.0	1.0	1.0	1.0	0.46	-0.95	1.0	1.0	1.0	-0.09	1.0	0.03	-0.26		0.7
Property Plant Equipment	0.7	0.7	0.7	0.7	0.7	0.95	0.7	-0.7	-0.7	0.71	0.7	0.7	0.7	0.7	0.7	0.89	-0.67	0.7	0.7	0.7	-0.12	0.7	0.58	0.33	0.7

Click cells to compare fundamentals

Zymeworks Common Account Relationship Matchups

Zymeworks Common balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	538.4M	389.1M	648.7M	580.9M	463.1B	486.2B
Other Current Liab	76.7M	65.4M	61.7M	39.8M	62.7B	65.8B
Total Current Liabilities	85.7M	71.9M	95.6M	55.8M	88.3B	92.7B
Total Stockholder Equity	409.9M	249.1M	493.0M	464.8M	338.8B	355.7B
Other Liab	34.3M	37.0M	37.3M	35.4M	40.7M	22.5M
Net Tangible Assets	227.6M	375.0M	215.6M	472.2M	543.0M	570.2M
Property Plant And Equipment Net	17.6M	49.8M	47.7M	37.5M	34.3B	36.0B
Net Debt	(233.4M)	(169.5M)	(372.8M)	(130.8M)	(47.6B)	(45.2B)
Retained Earnings	(471.3M)	(683.1M)	(558.8M)	(677.4M)	(830.3B)	(788.8B)
Accounts Payable	6.2M	5.2M	7.9M	6.2M	3.9M	4.6M
Cash	242.0M	201.9M	400.9M	157.6M	66.1B	69.4B
Non Current Assets Total	83.3M	100.9M	104.0M	168.0M	162.6B	170.8B
Non Currrent Assets Other	3.1M	13.7M	15.7M	7.3M	107.3B	112.7B
Cash And Short Term Investments	426.4M	252.6M	492.2M	374.3M	225.8B	237.1B
Net Receivables	15.3M	15.6M	33.4M	19.5M	55.8B	58.6B
Common Stock Shares Outstanding	50.4M	52.1M	65.2M	68.9M	75.9M	46.0M
Liabilities And Stockholders Equity	538.4M	389.1M	648.7M	580.9M	463.1B	486.2B
Other Current Assets	26.9M	40.0M	19.1M	19.1M	18.9B	19.8B
Other Stockholder Equity	163.6M	197.7M	151.6M	142.3M	160.4B	168.5B
Total Liab	128.5M	140.0M	155.8M	116.1M	124.3B	130.5B
Total Current Assets	455.1M	288.2M	544.7M	412.9M	300.5B	315.5B
Short Term Debt	2.7M	1.3M	6.6M	28.5M	2.7M	4.3M
Intangible Assets	22.9M	21.5M	26.4M	25.3M	4.6M	4.3M
Common Stock	724.2M	741.1M	906.8M	1.0B	1.0T	1.1T
Property Plant Equipment	16.5M	12.2M	22.8M	47.7M	54.8M	57.5M
Short Long Term Debt Total	8.6M	32.3M	28.1M	26.7M	18.5B	19.4B
Current Deferred Revenue	37.4M	57.6M	2.4M	3.7M	25.6B	26.9B
Other Assets	21.8M	65.8M	34.4M	34.7M	39.9M	30.9M
Common Stock Total Equity	320.1M	450.2M	724.2M	741.1M	852.3M	894.9M
Short Term Investments	184.3M	50.7M	91.3M	216.8M	159.7B	167.7B
Non Current Liabilities Total	42.8M	68.2M	60.1M	60.3M	36.0B	37.8B
Capital Surpluse	12.3M	92.8M	163.6M	197.7M	227.4M	238.7M
Deferred Long Term Liab	18.3M	34.1M	34.5M	17.6M	20.3M	22.5M
Property Plant And Equipment Gross	12.2M	63.8M	60.9M	58.2M	52.1M	34.9M
Capital Lease Obligations	8.6M	41.2M	28.1M	26.7M	18.5M	15.9M
Non Current Liabilities Other	8.7M	33.7M	3.0M	1.6M	895K	850.3K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ZLAB	Zai Lab
ASLE	AerSale Corp
ATS	AT S Austria

When determining whether Zymeworks Common Stock is a strong investment it is important to analyze Zymeworks Common's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Zymeworks Common's future performance. For an informed investment choice regarding Zymeworks Stock, refer to the following important reports:

How To Invest In Zymeworks

Details

Is Zymeworks Stock a good investment?

Details

What is Zymeworks Common's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Zymeworks Common. If investors know Zymeworks will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Zymeworks Common listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.62)

Revenue Per Share

1.006

Quarterly Revenue Growth

0.833

Return On Assets

(0.15)

Return On Equity

(0.31)

The market value of Zymeworks Common Stock is measured differently than its book value, which is the value of Zymeworks that is recorded on the company's balance sheet. Investors also form their own opinion of Zymeworks Common's value that differs from its market value or its book value, called intrinsic value, which is Zymeworks Common's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Zymeworks Common's market value can be influenced by many factors that don't directly affect Zymeworks Common's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Zymeworks Common's value and its price as these two are different measures arrived at by different means. Investors typically determine if Zymeworks Common is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Zymeworks Common's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Zymeworks Historical Balance Sheet

About Zymeworks Balance Sheet Analysis

Zymeworks Common Balance Sheet Chart

Total Assets

Total Current Liabilities

Zymeworks Common balance sheet Correlations

Zymeworks Common Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Zymeworks Common balance sheet Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Other Current Liab	+ 1.0	Total Assets
Total Current Liabilities	+ 1.0	Total Assets
Total Stockholder Equity	+ 1.0	Total Assets
Property Plant And Equipment Net	+ 1.0	Total Assets
Cash	+ 1.0	Total Assets
Non Current Assets Total	+ 1.0	Total Assets

Common Stock	- 1.0	Retained Earnings
Total Current Assets	- 1.0	Retained Earnings
Total Liab	- 1.0	Retained Earnings
Other Stockholder Equity	- 1.0	Retained Earnings
Other Current Assets	- 1.0	Retained Earnings
Net Receivables	- 1.0	Retained Earnings